
 **Treatment Updates in Demyelinating Disorders of CNS and Myasthenia Gravis (10/10/25) | 10/10/2025 8:00 AM Hybrid - Gem Theatre & Microsoft Teams**

The past few years have been very exciting in the multiple sclerosis ( MS), demyelinating disorders of central nervous system ( NMOSD, MOGAD) and myasthenia gravis ( MG) field. There have been quite a few new treatments approved lately for management of MS, NMOSD, MG. We have gathered some of the best experts in neurology, infection disease, hepatology, surgery and obstetrics to answer the most commonly encountered questions regarding the complex treatment management and monitoring of patients with MS, NMOSD, MG.

**Program Goal**

1 Demonstrate knowledge of diagnosis criteria of multiple sclerosis and demyelinating disorders of central nervous system.

2 Demonstrate knowledge of Myasthenia gravis classification and clinical assessment

3 Demonstrate knowledge of new immunomodulatory and immunosuppressive treatments of MS, NMOSD, MG and monitoring requirements of each treatment

4 Address and discuss with patients' treatment of MS, NMOSD, MG in pregnancy, postpartum/breastfeeding

5 Become familiar with plasma exchange treatment in acute presentations of MS, NMOSD, MG

6 Demonstrate familiarity with surgical treatment indication for MG

7 Demonstrate familiarity with required immunization, treatment of infections with immunosuppressive therapy for MS, NMOSD, MG

**Target Audience** Family Medicine, Internal Medicine, Neurology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Luisa Bazan, MD | Faculty | Nothing to disclose - 05/13/2025 |
| Neil Simmerman, MD | Faculty | Advisor-Cooper Surgical|Advisor-Natera - 11/13/2024 |
| Odaliz Abreu Lanfranco, MD | Faculty | Nothing to disclose - 04/23/2025 |
| Mirela Cerghet, MD | Co-Director, Faculty | Nothing to disclose - 04/21/2025 |
| Helena Bulka, DO | Faculty | Nothing to disclose - 05/13/2025 |
| Anza Memon, MD | Faculty | Consulting Fee-Inlightened and Connected Research|Grant or research support-NIH|Grant or research support-Genentech - 04/20/2025 |
| Andrew Popoff, MD | Faculty | Consulting Fee-Astrazeneca (Relationship has ended)|Consulting Fee-Oxford Performance Materials - 03/26/2025 |
| Deepak Venkat, MD | Faculty | Nothing to disclose - 04/23/2025 |
| Kavita Grover, MD | Co-Director, Faculty | Advisor-Janssen (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen|Advisor-Amgen (Relationship has ended)|Advisor-UCB (Relationship has ended)|Advisor-Kyverna (Relationship has ended) - 05/12/2025 |
| Ileana Lopez-Plaza, MD | Faculty | Nothing to disclose - 05/30/2025 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/07/2025 |
| Nicole Hammermeister | Activity Coordinator | Nothing to disclose - 01/22/2025 |
| Sara Pomponio, RN, BSN | Other Planning Committee Member | Nothing to disclose - 03/06/2025 |
| Alyssa Smith, BS | CME Specialist | Nothing to disclose - 01/22/2025 |
| Nestelynn Gay, MS | Other Planning Committee Member | Nothing to disclose - 05/14/2025 |
| Abbas Jowkar, MD, FAAN | Faculty | Nothing to disclose - 04/25/2025 |
| Ata, Syed, PhD | Faculty | Nothing to disclose - 05/14/2025 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 6.00 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Please allow a minimum of 3 days to process this request.